The total return over the past 12 months is +54.20% vs. +16.94% for the S&P 500. So far it's up +58.54% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +54.20% | +22.99% | +0.65% | +2.46% | +3.43% | +3.59% |
| Total Return CAGR | +54.20% | +22.99% | +0.65% | +2.46% | +3.43% | +3.59% |
| Revenue CAGR | +8.49% | +25.05% | +13.74% | +11.29% | +13.17% | +9.73% |
| Net Income CAGR | (55.31%) | N/A | N/A | (3.14%) | N/A | +0.66% |
| EPS CAGR | (54.83%) | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | +138.91% | N/A | N/A | N/A | N/A | +8.63% |
| Operating Cash Flow CAGR | +132.62% | N/A | N/A | +14.30% | N/A | +9.45% |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
ImmuCell Corporation (ICCC)
| Year | Start price | End price | ICCC Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $6.15 | $9.75 | +58.54% | +14.51% | +44.03% |
| 2025 | $5.15 | $6.15 | +19.42% | +17.72% | +1.70% |
| 2024 | $5.09 | $5.15 | +1.18% | +24.89% | (23.71%) |
| 2023 | $6.10 | $5.09 | (16.56%) | +26.19% | (42.75%) |
| 2022 | $8.00 | $6.10 | (23.75%) | (18.17%) | (5.58%) |
| 2021 | $5.95 | $8.00 | +34.46% | +28.74% | +5.72% |
| 2020 | $5.15 | $5.95 | +15.53% | +18.37% | (2.84%) |
| 2019 | $7.05 | $5.15 | (26.91%) | +31.22% | (58.13%) |
| 2018 | $8.79 | $7.05 | (19.84%) | (4.56%) | (15.28%) |
| 2017 | $5.95 | $8.79 | +47.73% | +21.70% | +26.03% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
